Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.55 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | SHBG | P04278 | 4/20 | 0.50 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287861 | 1.00 | CYP19A1 (0.55) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| SCHEMBL9512557 | 1.00 | CYP19A1 (0.55) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| SCHEMBL12857149 | 1.00 | CYP19A1 (0.55) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| SCHEMBL1287860 | 1.00 | CYP19A1 (0.55) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| Water SCHEMBL27940020 | 0.99 | CYP19A1 (0.54) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| Hydrogen Peroxide SCHEMBL27824496 | 0.97 | CYP19A1 (0.53) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| Acetic Acid SCHEMBL31729653 | 0.94 | CYP19A1 (0.50) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| Sulfuric Acid SCHEMBL5532907 | 0.94 | CYP19A1 (0.50) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| SCHEMBL29757161 | 0.85 | GRIN1 (0.43) | CYP19A1AKR1B10AKR1B1OR51E2LMNA | |
| SCHEMBL874928 | 0.84 | CYP19A1 (0.52) | CYP19A1AKR1B10AKR1B1OR51E2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346385-A1 | TASTE-MASKED DOSAGE FORMS | DEEP OCEAN CAPITAL MANAGEMENT LP | 2021-11-11 | — | — | US | disclosed |
| WO-2020061584-A1 | TASTE-MASKED DOSAGE FORMS | MSB HOLDINGS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3172566-B1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LTD (GB) | 2019-10-16 | — | — | EP | disclosed |
| US-20170307605-A1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3172566-A1 | SAMPLE ANALYSING DEVICE | Intelligent Fingerprinting Limited (GB) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012812-A1 | SAMPLE ANALYSING DEVICE | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2016-01-28 | — | — | WO | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| US-20150152348-A1 | SYSTEMS AND METHODS FOR COLLECTING, TRANSPORTING AND REPURPOSING OR DESTROYING UNUSED PHARMACEUTICALS | SHARPS COMPLIANCE, INC. OF TEXAS | 2015-06-04 | — | — | US | disclosed |
| US-8455264-B2 | Fluorescence based detection of substances | INTELLIGENT FINGERPRINTING LIMITED (GB) | 2013-06-04 | — | — | US | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | disclosed |
| US-6391868-B2 | Use of 5-alpha-androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17-beta-hydroxy-5-alpha-androst-1-en-3-one in humans | LPT RESEARCH, INC. | 2002-05-21 | — | — | US | disclosed |
| US-20010056087-A1 | Use of 5alpha-androst-1en-3,17-diol to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-12-27 | — | — | US | disclosed |
| US-20010041698-A1 | Use of 5alpha -androst-1-en-3,17-dione to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans | ARNOLD PATRICK (US) | 2001-11-15 | — | — | US | disclosed |
| US-4904650-A | Substituted androsta-1,4-diene-3,17-diones | FARMITALIA CARLO ERBA S.P.A. (IT) | 1990-02-27 | — | — | US | disclosed |
| US-4808616-A | 6-substituted androsta-1,4-diene-3,17-diones | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-02-28 | — | — | US | disclosed |
| US-4139717-A | 1,3-Dicarbonyl compounds | TEIJIN LIMITED (JP) | 1979-02-13 | — | — | US | disclosed |
| US-4009196-A | HYPOTENSIVE AGENTS, BRONCHODILATORS, PROSTAGLANDIN ANALOGS | TEIJIN LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
| US-3931154-A | Process for the preparation of steroid oxiranes | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | CYP19A1 3/4885AKR1B10 139/4885AKR1B1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.